

Commercial Pharmacy Benefit Change

Neighborhood News – July 2025

Effective **July 1, 2025**, Neighborhood will update its **Commercial Pharmacy Benefit** to remove Stelara from the Commercial Formulary. Going forward, **only the following Ustekinumab biosimilars will be preferred:**

- **Otulfi**
- **Selarsdi**
- **Steqeyma**
- **Yesintek**

ALL Commercial adult members currently prescribed Stelara must obtain a new prescription for one of the preferred biosimilars listed above. **Existing authorizations for Stelara have been terminated as of July 1, 2025.**

For pediatric members:

- Pediatric members **currently using Stelara may continue treatment without change.**
- Pediatric patients **new to ustekinumab therapy** will be directed to begin treatment with a **preferred biosimilar**, if clinically appropriate